Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21569587 | 0.89 | HRH4 (0.44) | HRH4HRH3 | |
| SCHEMBL13958915 | 0.82 | HRH4 (0.32) | HRH4HRH3 | |
| SCHEMBL22508014 | 0.80 | ALDH1A1 (0.35) | KDM4EALDH1A1 | |
| SCHEMBL2893056 | 0.79 | HRH4 (0.38) | HRH4HRH3ALDH1A1 | |
| SCHEMBL14707751 | 0.79 | IDO1 (0.32) | — | |
| SCHEMBL119179 | 0.79 | — | — | |
| SCHEMBL22508015 | 0.78 | — | — | |
| SCHEMBL31364605 | 0.78 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL31364603 | 0.78 | ALDH1A1 (0.31) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1308667 | 0.78 | HRH4 (0.37) | HRH4HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220412961-A1 | DEVICE AND METHOD FOR ANALYTE DETECTION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-12-29 | — | — | US | disclosed |
| US-10669253-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-10464925-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-10266531-B2 | Naphthyridinone derivatives and their use in the treatment of arrhythmia | NOVARTIS AG (CH) | 2019-04-23 | — | — | US | disclosed |
| US-20190071415-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-03-07 | — | — | US | disclosed |
| US-20180134684-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180134684-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180009779-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-01-11 | — | — | US | disclosed |
| US-20090292119-A1 | METHODS FOR SYNTHESIZING BENZOTHIAZEPINE COMPOUNDS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-11-26 | — | — | US | disclosed |
| US-7235541-B2 | Neurokinin antagonists for use as medicaments | ASTRAZENECA AB (SE) | 2007-06-26 | — | — | US | disclosed |
| US-7235541-B2 | Neurokinin antagonists for use as medicaments | ASTRAZENECA AB (SE) | 2007-06-26 | — | — | US | disclosed |
| US-20070021406-A1 | New neurokinin antagonists for use as medicaments | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | US | disclosed |
| US-20070021406-A1 | New neurokinin antagonists for use as medicaments | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071415-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | HRH4 3823/4885HRH3 3634/4885KDM4E 3648/4885 |
| US-20180009779-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | HRH4 3823/4885HRH3 3634/4885KDM4E 3648/4885 |
| US-10266531-B2 | Naphthyridinone derivatives and their use in the treatment of arrhythmia | SCN1B, NPR3, SCN3A | HRH4 387/4885HRH3 257/4885KDM4E 1891/4885 |
| US-20220412961-A1 | DEVICE AND METHOD FOR ANALYTE DETECTION | SPR, EZR, CD2BP2 | HRH4 4535/4885HRH3 4302/4885KDM4E 4751/4885 |
| US-20070021406-A1 | New neurokinin antagonists for use as medicaments | NPSR1, HRH4, OPRL1 | HRH4 2/4885HRH3 10/4885KDM4E 3617/4885 |
| US-10464925-B2 | Methods to induce targeted protein degradation through bifunctional molecules | CRBN, MDM2, MYCBP | HRH4 3823/4885HRH3 3634/4885KDM4E 3648/4885 |
| US-20090292119-A1 | METHODS FOR SYNTHESIZING BENZOTHIAZEPINE COMPOUNDS | KCNB2, KCNJ2, KCNJ5 | HRH4 599/4885HRH3 1063/4885KDM4E 477/4885 |
| US-10669253-B2 | Methods to induce targeted protein degradation through bifunctional molecules | CRBN, SMARCE1, MDM2 | HRH4 3907/4885HRH3 3106/4885KDM4E 2734/4885 |
| US-20180134684-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | HRH4 3823/4885HRH3 3634/4885KDM4E 3648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.